CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a clinical-stage biotech firm focused on cancer treatment. The company is committed to advancing conditionally activated masked biologics that are designed to selectively engage and function within the tumor microenvironment.

As per previous Kalkine’s Diversified Opportunities Report published on ‘CTMX’ on Sep 25, 2025, Kalkine provided an ‘Buy’ stance on the stock at USD 2.33 based on fundamental analysis and the stock price has now moved up by ~ 38.63% since then and has breached resistance level 2.

Noted below are the details of support and resistance levels provided in our previous report:

Rationale:

• Declining Revenue Base: CytomX experienced a year-over-year decline in revenues, falling from USD 25.1 million in Q2 2024 to USD 18.7 million in Q2 2025. This drop was largely due to the completion of obligations in its Bristol Myers Squibb collaboration, the decision not to further develop the CX-904 program under its Amgen agreement, and budget constraints impacting Moderna activities. Such contraction in collaboration revenue underscores the company’s reliance on external partnerships, raising concerns about the sustainability of its income streams.
• Heavy Dependence on Key Clinical Assets: The company’s pipeline is highly concentrated, with its future growth largely tied to the success of CX-2051 and CX-801. Both are still in early-to-mid clinical stages, with CX-2051 only in Phase 1 dose expansions and CX-801 in preliminary trials. The unproven nature of these assets creates significant uncertainty, as any setbacks in clinical trials, safety outcomes, or regulatory reviews could derail the company’s prospects and prolong its path to commercialization.
• Financial Risks Despite Cash Infusion: Although CytomX completed a USD 100 million equity offering, boosting cash reserves to USD 158.1 million, the company remains in a loss-making position, reporting a net loss of USD 154,000 in Q2 2025. The company continues to burn cash on R&D and operations, and while the current runway extends into 2027, long-term viability will require additional funding unless a product reaches commercialization. This reliance on external financing leaves shareholders exposed to further dilution and market risks.
• Operational and Strategic Uncertainties: The company’s recent restructuring and program de-prioritizations, such as scaling back CX-904, highlight challenges in maintaining a diversified and balanced pipeline. Moreover, dependence on third-party manufacturers and collaborators introduces execution risks outside the company’s control. Coupled with the inherently uncertain nature of drug development, including the risk that early positive results may not translate into later-stage success, CytomX faces a precarious strategic outlook that could impact investor confidence.

Valuation (Using EV/Sales Multiple)

Share Price Chart

Conclusion

Based on the strong ∼39% performance of CTMX shares since our initial coverage, investors have realized decent notional gains. However, a technical analysis indicates the stock is currently overbought, with the 14-Day Relative Strength Index (RSI) substantially above 90. Considering this overbought technical signal, the potential for valuation downside, and the opportunity to lock in gains, we are issuing a "Sell" recommendation on CytomX Therapeutics, Inc. (NASDAQ: CTMX). This recommendation is initiated at the closing market price of USD 3.23 as of September 29, 2025.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is 29 September 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level which the stock is expected to reach as per the relative valuation method and/or technical analysis taking into consideration both short-term and long-term scenario.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’

Note 6: Dividend Yield may vary as per the stock price movement.